Personalised medicine in prostate cancer.
[Personalised medicine in prostate cancer]. Aktuelle Urol. 2019 Sep;50(5):509-512 Authors: Pfister D, Haidl F, Paffenholz P, Nestler T, Heidenreich A Abstract Prostate cancer is the most common cancer in men. Its incidence increases with age. New treatment options have been introduced and there is a clear trend to more aggressive treatment in newly diagnosed metastatic disease. While prolonged survival of patients has been achieved, the new expensive drugs are associated with an increased burden on the healthcare system. Meanwhile, similarly to other tumour entities, there is a pool of different drugs available with comparable oncologic efficacy, but different side-effects. Effective diagnostic investigation and treatment decisions require additional factors, above and beyond clinical parameters, for a more individual treatment approach. In castration-resistant prostate cancer (CRPCA), there are promising molecular markers for treatment decisions. In metastatic disease, liquid biopsies and next generation sequencing of metastatic biopsies allow for genetic analysis. These will provide more insight into tumour dynamics and allow for patient selection. This review concentrates on molecular markers in CRPCA. PMID: 31466098 [PubMed - in process]
CONCLUSIONS: AI technologies are growing their role in health care; but, up to now, their "real-life" implementation remains limited. However, in the near future, the potential of AI-driven era could change the clinical practice in Urology, improving overall patient outcomes. PMID: 31833725 [PubMed - as supplied by publisher]
CONCLUSIONS: Our data show high adherence and persistence rates in men on ADT. The overall survival in the super-elderly is not influenced by persistence and/or adherence but rather by co-prescriptions. PMID: 31833723 [PubMed - as supplied by publisher]
CONCLUSIONS: ORP, ePLND and seminal vesicle invasion are independent predictors of the risk of hospital readmission over the long term at a large single tertiary referral center. When surgery is chosen as a primary treatment of PCA, patients should be informed of the risk of hospital readmission and related risk factors. Assessing seminal vesicle invasion by preoperative clinical staging identifies locally advanced disease, which is associated with an increased risk of hospital readmission. PMID: 31833722 [PubMed - as supplied by publisher]
CONCLUSIONS: Three USP steroids resulted significantly altered in our PCa population. These preliminary results, combined with the simplicity and low-cost of the analysis, open to further investigation of the potential role of this restricted USP in PCa diagnosis. PMID: 31833333 [PubMed - as supplied by publisher]
Conclusion: MiR-7-5p suppresses NSCLC metastasis. Targeting miR-7-5p may contribute to the success of NSCLC therapy. PMID: 31832068 [PubMed - in process]
Publication date: Available online 9 December 2019Source: Sensors and Actuators B: ChemicalAuthor(s): Omid Sheydaei, Habibollah Khajehsharifi, Hamid Reza RajabiAbstractThe presence of sarcosine (SAR) in the human urine was recently suggested as a promising biomarker for prostate cancer (PCa) diagnostics. In this work, we have developed the electrochemical methods for selective determination of sarcosine (SAR) in urine samples, based on the modification of the carbon paste electrode (CPE) using uniform nano-scaled molecularly imprinted polymer (MIP). The uniform MIP nanobeads were prepared by a simple sol-gel method, using ...
Conclusion: According to these data, monitoring this class of toxicities is of primary importance to avoid hypertension worsening and, thus, the risk of major cardiovascular events. PMID: 31829045 [PubMed - as supplied by publisher]
Publication date: Available online 13 December 2019Source: European UrologyAuthor(s): Nobuaki Matsubara, Kim N. Chi, Mustafa Özgüroğlu, Alfredo Rodriguez-Antolin, Susan Feyerabend, Luis Fein, Boris Y. Alekseev, Giri Sulur, Andrew Protheroe, Susan Li, Suneel Mundle, Peter De Porre, Namphuong Tran, Karim FizaziAbstractBackgroundLATITUDE, a randomized, double-blind trial, compared abiraterone acetate and prednisone (AAP) + androgen deprivation therapy (ADT) versus placebo (PBO) + ADT in high-risk metastatic castration-sensitive prostate cancer (mCSPC).ObjectiveTo assess the correlation of prostate-specific antigen ...
Publication date: Available online 13 December 2019Source: European UrologyAuthor(s): Ausvydas Patasius, Giedre Smailyte
Conclusion: In conclusion, our study reveals that elevated MRE11 expression is significantly correlated with cancer progression and poor survival in PCa patients. These data suggest that MRE11 may act as an oncoprotein and a promising prognostic marker for PCa patients.